Regeneron Pharmaceuticals REGN Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's interest expense?
- Regeneron Pharmaceuticals (REGN) reported interest expense of $12.9M in Q1 2026.
- How has Regeneron Pharmaceuticals's interest expense changed year-over-year?
- Regeneron Pharmaceuticals's interest expense increased by 48.3% year-over-year, from $8.7M to $12.9M.
- What is the long-term trend for Regeneron Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's interest expense has grown at a -6.5% compound annual growth rate (CAGR), from $57.3M to $43.8M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.